Predicting risk of coronary events and all-cause mortality: role of B-type natriuretic peptide above traditional risk factors and coronary artery calcium scoring in the general population: the Heinz Nixdorf Recall Study
暂无分享,去创建一个
S. Moebus | K. Jöckel | S. Möhlenkamp | R. Erbel | N. Dragano | H. Kälsch | N. Lehmann | M. Bauer | A. Mahabadi | T. Neumann | K. Kara | Marie H. Berg
[1] C. Lang,et al. Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. , 2012, Journal of the American College of Cardiology.
[2] M. Cameli,et al. B-type natriuretic peptide as an independent predictor of coronary disease extension in non-ST elevation coronary syndromes with preserved systolic function , 2012, European journal of preventive cardiology.
[3] M. Volpe,et al. Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. , 2012, International journal of cardiology.
[4] Sex-specific threshold levels of plasma B-type natriuretic peptide for prediction of cardiovascular event risk in a Japanese population initially free of cardiovascular disease. , 2011, The American journal of cardiology.
[5] S. Moebus,et al. Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. , 2011, Journal of the American College of Cardiology.
[6] Lloyd E Chambless,et al. Several methods to assess improvement in risk prediction models: Extension to survival analysis , 2011, Statistics in medicine.
[7] Klaus Mann,et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. , 2010, Journal of the American College of Cardiology.
[8] A. Hofman,et al. Amino-Terminal Pro–B-Type Natriuretic Peptide Improves Cardiovascular and Cerebrovascular Risk Prediction in the Population: The Rotterdam Study , 2010, Hypertension.
[9] D. de Zeeuw,et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. , 2010, European heart journal.
[10] J. Danesh,et al. B-Type Natriuretic Peptides and Cardiovascular Risk: Systematic Review and Meta-Analysis of 40 Prospective Studies , 2009, Circulation.
[11] D. Berman,et al. Prognostic accuracy of B-natriuretic peptide measurements and coronary artery calcium in asymptomatic subjects (from the Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research [EISNER] study). , 2009, The American journal of cardiology.
[12] M. Pencina,et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. , 2009, JAMA.
[13] D. Grönemeyer,et al. Smoking cessation and subclinical atherosclerosis--results from the Heinz Nixdorf Recall Study. , 2009, Atherosclerosis.
[14] R. Kronmal,et al. Coronary calcium predicts events better with absolute calcium scores than age-sex-race/ethnicity percentiles: MESA (Multi-Ethnic Study of Atherosclerosis). , 2009, Journal of the American College of Cardiology.
[15] J. Sundström,et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes , 2008 .
[16] D. Grönemeyer,et al. Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation. , 2008, Atherosclerosis.
[17] Moyses Szklo,et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. , 2008, The New England journal of medicine.
[18] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[19] S. Moebus,et al. Comparison of subclinical coronary atherosclerosis and risk factors in unselected populations in Germany and US-America. , 2007, Atherosclerosis.
[20] Mark A. Hlatky,et al. ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring By Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain , 2007 .
[21] Daniel S Berman,et al. Coronary artery calcium as a measure of biologic age. , 2006, Atherosclerosis.
[22] D. Grönemeyer,et al. Population-based assessment of subclinical coronary atherosclerosis using electron-beam computed tomography. , 2006, Atherosclerosis.
[23] R. Redberg. Coronary artery calcium: should we rely on this surrogate marker? , 2006, Circulation.
[24] A. Khera,et al. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas Heart Study). , 2005, The American journal of cardiology.
[25] C. Camargo,et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.
[26] D. Levy,et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death , 2004 .
[27] J. Rehfeld,et al. Increased cardiac BNP expression associated with myocardial ischemia , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[28] P. Ferdinandy,et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. , 2003, American journal of physiology. Heart and circulatory physiology.
[29] D. Grönemeyer,et al. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. , 2002, American heart journal.
[30] Alan S Maisel,et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.
[31] M. Ohyanagi,et al. Transient increase in plasma brain (b‐type) natriuretic peptide after percutaneous transluminal coronary angioplasty , 2000, Clinical cardiology.
[32] K. Bailey,et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. , 1996, Hypertension.
[33] H. Itoh,et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. , 1995, Circulation.
[34] K. Kugiyama,et al. Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.
[35] Z. Ying,et al. Checking the Cox model with cumulative sums of martingale-based residuals , 1993 .
[36] S. Yusuf,et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.
[37] R. Detrano,et al. Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.
[38] David A. Schoenfeld,et al. Partial residuals for the proportional hazards regression model , 1982 .